| Objective:To study expression of Th1 type cytokine and Th2 type cytokine in human breast carcinoma tissues and the relationship between Th1/Th2 and clinicopathological characteristics in breast cancer.Methods: The expression of IL-2, IFN-γ, IL-4 and IL-10 were detected by immunohistochemistry in 43 young human breast carcinoma tissues, 52 old human breast carcinoma tissues, 10 breast fibroadenoma tissues and 10 normal breast tissues, using IL-2 and IFN-γas Th1 cytokine and IL-4 and IL-10 as Th2 cytokine.Results:①IL-2 positive expression rate in breast carcinoma group was 34.74%(33/95), IFN-γpositive expression rate was 48.4%(46/95), the positive expression rate of IL-2, IFN-γin breast carcinoma tissues was significant lower than in breast fibroadenoma tissues and normal breast tissues(P<0.01); IL-4 positive expression rate in breast carcinoma group was 88.4%(84/95), IL-10 positive expression rate in breast carcinoma group was 90.5%(86/95), the positive expression rate of IL-4, IL-10 in breast carcinoma tissues was significant higher than in breast fibroadenoma tissues and normal breast tissues(P<0.01).②IL-2 positive expression rate in young human breast carcinoma group was 14%(6/43),that was lower than IL-2 positive expression rate in old human breast carcinoma tissues(51.9%,27/52) (P<0.01); IFN-γpositive expression rate in young human breast carcinoma group was 41.9%(18/43), that was lower than IFN-γpositive expression rate in old human breast carcinoma tissues(53.8%,28/52)(P=0.103).③IL-4 positive expression rate in young human breast carcinoma group was 88.4%, and in old human breast carcinoma group was 88.5%; IL-10 positive expression rate in young human breast carcinoma group was 90.7%, and in old human breast carcinoma group was 90.4%. The positive expression rate of IL-4, IL-10 were not significant different between young human breast carcinoma group and old human breast carcinoma group(P>0.05).④The positive expression rate of IL-2 was decreased followed to the increasing of clinical staging (P<0.05).⑤There were higher expression of IL-4 in metastasis of lymph node than no metastasis of lymph node of young and old human breast carcinoma(P<0.05).Conclusion:①The expression of Th1 cytokines was inhibited with a concomitant predominant state of Th2 cytokines in tumor tissues from breast cancer patients. The balance between Th1 and Th2 was shifted to the direction of Th2.②The shift was more obviously in young breast carcinoma tissues than in old breast carcinoma tissues.③The combinating detection of IL-2, IL-4 expression may assess the clinical prognosis of breast carcinoma. Objective:To investigate the relationship of the expression of IL-2 and IL-4 in breast cancer cells with chemosensitivity.Methods: Surgical samples of breast cancer,diagnosed by pathology, originated from The First Affiliated Hospital of Chongqing Medical University. The cancer sample cells were cultured separately in the incubator at 37℃,5%CO2 in vitro. The rate of inhibition of cancer cells by 4 kinds of anticancer drugs, which were EADM, 5-Fu, NVB and DDP, were assayed by MTT method. Immunohistochemistry was used to detect the expression of IL-2 and IL-4 in the breast cancer tissues.Results: Sensitivity rate of 20 breast cancer cells in 0.1×PPC within 48h in vitro were 30%(EADM), 20%(5-Fu), 45%(NVB)and 25%( DDP). The rate of inhibition of EADM, 5-Fu, NVB and DDP were significantly higher in the IL-2 positive cancer cells than in the IL-2 negative cancer cells. A positive correlation was found between expression of IL-2 and chemosensitivity for all the 4 anticancer drugs. The rate of inhibition of EADM and NVB were significantly lower in the IL-4 positive cancer cells than in the IL-4 negative cancer cells. A negative correlation was found between expression of IL-4 and chemosensitivity for the 2 anticancer drugs.Conclusions: The expression of IL-2 and IL-4 are related with the chemosensitivity of the breast cancer cells, and they may become one of the markers for judging the effect of chemotherapy in clinic. The combinating detection of IL-2 and IL-4 may be taken as an index of the selection of anticancer drugs. |
PDF Full Text Request